Canaccord Genuity Downgrades AcelRx Pharmaceuticals To Hold

Analysts at Canaccord Genuity downgraded AcelRx Pharmaceuticals

from Buy to Hold. The target price for AcelRx Pharmaceuticals has been lowered from $16.00 to $8.00. AcelRx Pharmaceuticals shares have dropped 7.83% over the past 52 weeks, while the S&P 500 index has gained 17.39% in the same period. AcelRx Pharmaceuticals' shares dropped 30.84% to $7.49 in pre-market trading.